In April, Unilife Corp (NASDAQ:UNIS) agreed to preliminary terms with a leading U.S. life science financing firm for a debt funding program that is expected to be finalized at the end of this month. Combined with the anticipated revenue to be generated from new and existing customer agreements, this medium-term debt program is expected to strengthen the company’s balance sheet and minimize potential dilution to existing shareholders.
Investors are waiting patiently for the announced contracts to kick in. The stock price has already reacted accordingly. From $1.85 on May 9 to $3.82 on May 24.
A very upbeat story that has pleased investors so far. Let’s see what happens going forward.
The challenge for medical device companies is going to be coming up with devices that both have a healthcare benefit but also a demonstrable a cost lowering effect. Promising technologies for the coming years include innovations that address chronic diseases, improve diagnosis, treat conditions less invasively, reduce patients’ dependence on drugs, and many more emerging technologies. I think the four companies mentioned above are a great start for investors looking for exposure in this sector.
Johan Seijkens has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic.
The article The Medical Device Industry Offers Opportunities originally appeared on Fool.com.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.